Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of s-ketamine effects on reducing suicidal thoughts and behaviors in major depressive disorder
IRCT20160105025859N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of esketamine in major depressive disorder (MDD), suicidal ideation and Suicidality, sponsored by Shiraz University of Medical Sciences. Started May 2019; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)suicidal ideationSuicidality
Beyond the preview
Go deeper on IRCT20160105025859N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160105025859N1.